Development and assessment of 153Sm-zoledronate complex as a possible bone pain palliative agent

Mirsaeed Nikzad; Amir Reza Jalilian; Simindokht Shirvani-Arani; Masood  Arabieh; Saeed Shanehsazzadeh; Hamid Golchoobian

Development and assessment of 153Sm-zoledronate complex as a possible bone pain palliative agent

Mirsaeed Nikzad, Amir Reza Jalilian, Simindokht Shirvani-Arani, Masood Arabieh, Saeed Shanehsazzadeh, Hamid Golchoobian

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

Introduction: In this work, Sm-153-zoledronate (Sm-153-ZLD) was studied using computational chemistry methods and prepared for possible use in bone pain palliation therapy.

Methods: The Sm(ZLD)(2).7H(2)O complex was synthesized and characterized in solid state using computational chemistry methods followed by Sm-153-ZLD complex production, stablity, hydroxyapatite (HA) tests and also biodictribution studies in animals were studied and used for absorbed dose determination in critical organs.

Results: The Sm(ZLD)(2).7H(2)O complex was synthesized and characterized in solid state and computational chemistry methods showed that 1:1, 1:2 and 1:3 complex formation are possible in aqueous solution. Sm-153-ZLD complex was prepared with >99% radiochemical purity (ITLC, HPLC) and specific activity of 4.4 GBq/mmol. It was stable for 24h with >95% binding to HA with accumulation in rat bones and kidneys. Absorbed dose showed kidney and osteogenic tissue as critical organs.

Conclusion: The Sm-153-ZLD complex data were compared to Sm-153-EDTMP and Sm-153-BPAMD.

Original language	English
Pages (from-to)	81-91
Number of pages	11
Journal	Iranian Journal of Nuclear Medicine
Volume	25
Issue number	2
Publication status	Published - Jan 2017
Externally published	Yes

Cite this

@article{28f470f10dda48ffb063b9437b17747d,

title = "Development and assessment of 153Sm-zoledronate complex as a possible bone pain palliative agent",

abstract = "Introduction: In this work, Sm-153-zoledronate (Sm-153-ZLD) was studied using computational chemistry methods and prepared for possible use in bone pain palliation therapy.Methods: The Sm(ZLD)(2).7H(2)O complex was synthesized and characterized in solid state using computational chemistry methods followed by Sm-153-ZLD complex production, stablity, hydroxyapatite (HA) tests and also biodictribution studies in animals were studied and used for absorbed dose determination in critical organs.Results: The Sm(ZLD)(2).7H(2)O complex was synthesized and characterized in solid state and computational chemistry methods showed that 1:1, 1:2 and 1:3 complex formation are possible in aqueous solution. Sm-153-ZLD complex was prepared with >99% radiochemical purity (ITLC, HPLC) and specific activity of 4.4 GBq/mmol. It was stable for 24h with >95% binding to HA with accumulation in rat bones and kidneys. Absorbed dose showed kidney and osteogenic tissue as critical organs.Conclusion: The Sm-153-ZLD complex data were compared to Sm-153-EDTMP and Sm-153-BPAMD.",

author = "Mirsaeed Nikzad and Jalilian, {Amir Reza} and Simindokht Shirvani-Arani and Masood Arabieh and Saeed Shanehsazzadeh and Hamid Golchoobian",

year = "2017",

month = jan,

language = "English",

volume = "25",

pages = "81--91",

journal = "Iranian Journal of Nuclear Medicine",

number = "2",

}

TY - JOUR

T1 - Development and assessment of 153Sm-zoledronate complex as a possible bone pain palliative agent

AU - Nikzad, Mirsaeed

AU - Jalilian, Amir Reza

AU - Shirvani-Arani, Simindokht

AU - Arabieh, Masood

AU - Shanehsazzadeh, Saeed

AU - Golchoobian, Hamid

PY - 2017/1

Y1 - 2017/1

N2 - Introduction: In this work, Sm-153-zoledronate (Sm-153-ZLD) was studied using computational chemistry methods and prepared for possible use in bone pain palliation therapy.Methods: The Sm(ZLD)(2).7H(2)O complex was synthesized and characterized in solid state using computational chemistry methods followed by Sm-153-ZLD complex production, stablity, hydroxyapatite (HA) tests and also biodictribution studies in animals were studied and used for absorbed dose determination in critical organs.Results: The Sm(ZLD)(2).7H(2)O complex was synthesized and characterized in solid state and computational chemistry methods showed that 1:1, 1:2 and 1:3 complex formation are possible in aqueous solution. Sm-153-ZLD complex was prepared with >99% radiochemical purity (ITLC, HPLC) and specific activity of 4.4 GBq/mmol. It was stable for 24h with >95% binding to HA with accumulation in rat bones and kidneys. Absorbed dose showed kidney and osteogenic tissue as critical organs.Conclusion: The Sm-153-ZLD complex data were compared to Sm-153-EDTMP and Sm-153-BPAMD.

AB - Introduction: In this work, Sm-153-zoledronate (Sm-153-ZLD) was studied using computational chemistry methods and prepared for possible use in bone pain palliation therapy.Methods: The Sm(ZLD)(2).7H(2)O complex was synthesized and characterized in solid state using computational chemistry methods followed by Sm-153-ZLD complex production, stablity, hydroxyapatite (HA) tests and also biodictribution studies in animals were studied and used for absorbed dose determination in critical organs.Results: The Sm(ZLD)(2).7H(2)O complex was synthesized and characterized in solid state and computational chemistry methods showed that 1:1, 1:2 and 1:3 complex formation are possible in aqueous solution. Sm-153-ZLD complex was prepared with >99% radiochemical purity (ITLC, HPLC) and specific activity of 4.4 GBq/mmol. It was stable for 24h with >95% binding to HA with accumulation in rat bones and kidneys. Absorbed dose showed kidney and osteogenic tissue as critical organs.Conclusion: The Sm-153-ZLD complex data were compared to Sm-153-EDTMP and Sm-153-BPAMD.

UR - https://irjnm.tums.ac.ir/article_26409_133994b6f2d7fdb02697869c46b60eee.pdf

M3 - Article

VL - 25

SP - 81

EP - 91

JO - Iranian Journal of Nuclear Medicine

JF - Iranian Journal of Nuclear Medicine

IS - 2

ER -

Development and assessment of 153Sm-zoledronate complex as a possible bone pain palliative agent

Abstract

Other files and links

Fingerprint

Cite this